주사용 약물전달 디바이스 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 치료 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Injectable Drug Delivery Devices Market Summary

The global injectable drug delivery devices market size was estimated at USD 114.7 billion in 2025 and is projected to reach USD 236.5 billion by 2033, growing at a CAGR of 9.6% from 2026 to 2033. This significant growth is fueled by an increasing need for advanced, effective, and user-friendly drug delivery solutions in various healthcare environments.

Key factors include the rising incidence of chronic diseases like diabetes, cancer, and autoimmune disorders that necessitate frequent injections. In addition, there is a growing preference for convenient injection instruments such as autoinjectors and pen injectors, alongside continuous technological innovations that improve safety, accuracy, and patient comfort. Moreover, the surge in biological developments, a shift toward home-based care, and an emphasis on minimizing hospital visits are all contributing to this upward trend in the market.

Another factor that influences the growth is the increasing demand for advanced, effective, and user-friendly drug delivery solutions in a variety of healthcare settings. Several key factors are at play, including the rising prevalence of chronic diseases like diabetes, cancer, and autoimmune disorders that require frequent injections. There's also a growing preference for convenient injection devices such as autoinjectors and pen injectors, coupled with ongoing technological advancements that enhance safety, accuracy, and patient comfort. In addition, the rise in biopharmaceutical innovations, a shift towards home-based care, and a focus on reducing hospital visits are all contributing to this positive market trend.

According to the World Health Organization (WHO), in 2022, there were approximately 20 million new cancer cases and 9.7 million deaths. By 2050, this figure is expected to surge by 77%, reaching over 35 million cases globally. Similarly, cardiovascular diseases (CVDs), such as coronary heart disease, cerebrovascular disease, and rheumatic heart disease, remain the leading cause of death worldwide, claiming an estimated 17.9 million lives annually.

Chronic diseases often require long-term treatment, making it challenging for many patients to stick to complex injectable regimens. Advanced drug delivery devices for injections help overcome these obstacles by making administration easier, reducing the frequency of doses, and minimizing errors. Autoinjectors and pen injectors streamline the injection process, promoting consistent dosing of biologics and specialty medications. Many next-generation devices also feature built-in dose reminders, connectivity for real-time monitoring, and digital tracking, all of which enhance adherence and enable patients to manage their treatment schedules more effectively. When adherence improves, it not only leads to better health outcomes but also decreases disease flare-ups, emergency visits, and overall healthcare costs.

Chronic diseases remain the leading and fastest-growing global health issue, responsible for nearly 75% of all deaths worldwide, as reported by the World Health Organization (WHO, 2024). Noncommunicable diseases (NCDs) like cardiovascular diseases, cancer, chronic respiratory illnesses, and diabetes cause approximately 41 million deaths annually. Low- and middle-income countries account for more than 77% of this mortality. The Global Burden of Disease (GBD) 2024 data indicate that over 1.3 billion people worldwide live with at least one chronic condition requiring continuous management, many of whom depend on injectable treatments such as insulin, monoclonal antibodies, and biologics. The increasing rates of obesity, sedentary lifestyles, and aging populations continue to intensify this issue.

Global Injectable Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 - 2033. For this study, Grand View Research has segmented the global injectable drug delivery devices market report based on product, therapeutic use, end use, and region:

• Product Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• Injectors
  • GLP-1 Agonists
  • Hormone Therapies
  • Biologics
  • Others
• Pen
  • GLP-1 Agonists
  • Insulin
  • Hormone Therapies
  • Others
• Therapeutic Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• Autoimmune Disorders
• Hormonal Disorders
• Oncology
• Obesity
• Diabetes Mellitus
• Others
• End Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Homecare Settings
• Others
• Regional Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Sweden
  • Denmark
• Asia
  • China
  • Japan
  • India
  • Thailand
  • South Korea
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product
  • 1.2.2. Drug Type
  • 1.2.3. Therapeutic Use
  • 1.2.4. End Use
• 1.3. Estimation and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Materials & Third-Party Perspectives
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
    • 1.8.1.1. Research Scope and Assumptions
    • 1.8.1.2. Research Methodology and Assumptions
  • 1.8.2. Volume Price Analysis
  • 1.8.3. CDMO injectable drug delivery devices Market
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations
• 1.11. Objectives
  • 1.11.1. Objective 1
  • 1.11.2. Objective 2
  • 1.11.3. Objective 3

Chapter 2. Executive Summary

• 2.1. Market Snapshot (Regional)
• 2.2. Segment Snapshot (Product)
• 2.3. Segment Snapshot (Therapeutic Use)
• 2.4. Segment Snapshot (End-use)
• 2.5. Market Concentration
• 2.6. Injectable Drug Delivery Devices Market Variables and Trends Market Lineage Outlook
• 2.7. Market Dynamics
  • 2.7.1. Market Driver Impact Analysis
  • 2.7.2. Market Restraint Analysis
  • 2.7.3. Market Opportunity Analysis
• 2.8. Industry Analysis Tools
  • 2.8.1. Porter's Five Forces Analysis
  • 2.8.2. Macroeconomic Analysis
• 2.9. List of CDMO Manufacturers and Supplied Injectable Drug Delivery Devices to Companies
  • 2.9.1. List of In-House Manufacturers of Injectable Drug Delivery Devices
  • 2.9.2. Qualitative Insights on Potential Impact of New Injectables or Oral Drugs and Development of Multi-Dose Devices, by Region
  • 2.9.3. North America
  • 2.9.4. Europe
  • 2.9.5. Asia
• 2.10. Global CDMO Injectable Drug Delivery Devices Market, by Product, 2021 - 2033 (value in USD Billion and Volume in Units Sold)
  • 2.10.1. Global CDMO Injectable Drug Delivery Devices Market, by Product, 2021 - 2033 (USD Billion)
  • 2.10.2. Global CDMO Injectable Drug Delivery Devices Market, by Product, 2021 - 2033 (Units)

Chapter 2. Injectable Drug Delivery Devices Market: Product Analysis

• 2.1. Product Movement Analysis & Market Share, 2025 & 2033
• 2.2. Injectable Drug Delivery Devices Market Estimates & Forecast, by Product (USD Billion, Units)
• 2.3. Market Size & Forecasts and Trend Analysis, 2021 - 2033
  • 2.3.1. Injectors
    • 2.3.1.1. Injectors Market, 2021 - 2033 (USD Billion, Units)
    • 2.3.1.2. GLP-1 Agonists
      • 2.3.1.2.1. GLP-1 Agonists Market, 2021 - 2033 (USD Billion, Units)
    • 2.3.1.3. Hormone Therapies
      • 2.3.1.3.1. Hormone Therapies Market, 2021 - 2033 (USD Billion, Units)
    • 2.3.1.4. Biologics
      • 2.3.1.4.1. Biologics Market, 2021 - 2033 (USD Billion, Units)
    • 2.3.1.5. Others
      • 2.3.1.5.1. Others Market, 2021 - 2033 (USD Billion, Units)
  • 2.3.2. Pens
    • 2.3.2.1. Pens Market, 2021 - 2033 (USD Billion, Units)
    • 2.3.2.2. GLP-1 Agonists
      • 2.3.2.2.1. GLP-1 Agonists Market, 2021 - 2033 (USD Billion, Units)
    • 2.3.2.3. Insulin
      • 2.3.2.3.1. Insulin Market, 2021 - 2033 (USD Billion, Units)
    • 2.3.2.4. Hormone Therapies
      • 2.3.2.4.1. Hormone Therapies Market, 2021 - 2033 (USD Billion, Units)
    • 2.3.2.5. Others
      • 2.3.2.5.1. Other Market Estimates & Forecasts, 2021 - 2033 (USD Billion, Units)

Chapter 3. Injectable Drug Delivery Devices Market: Therapeutic Use Estimates & Trend Analysis

• 3.1. Therapeutic Area Movement Analysis & Market Share, 2025 & 2033
• 3.2. Injectable Drug Delivery Devices Market Estimates & Forecast, by Therapeutic Use (USD Billion, Units)
• 3.3. Market Size & Forecasts and Trend Analysis, 2021 - 2033
  • 3.3.1. Autoimmune Disorders
    • 3.3.1.1. Autoimmune Disorders Market, 2021 - 2033 (USD Billion, Units)
  • 3.3.2. Hormonal Disorders
    • 3.3.2.1. Hormonal Disorders Market, 2021 - 2033 (USD Billion, Units)
  • 3.3.3. Oncology
    • 3.3.3.1. Oncology Market, 2021 - 2033 (USD Billion, Units)
  • 3.3.4. Obesity
    • 3.3.4.1. Obesity Market, 2021 - 2033 (USD Billion, Units)
  • 3.3.5. Diabetes Mellitus
    • 3.3.5.1. Diabetes Mellitus Market, 2021 - 2033 (USD Billion, Units)
  • 3.3.6. Others
    • 3.3.6.1. Others Market, 2021 - 2033 (USD Billion, Units)

Chapter 4. Injectable Drug Delivery Devices Market: End Use Analysis

• 4.1. End Use Movement Analysis & Market Share, 2025 & 2033
• 4.2. Injectable Drug Delivery Devices Market Estimates & Forecast, by End Use (USD Billion, Units)
• 4.3. Market Size & Forecasts and Trend Analysis, 2021 - 2033
  • 4.3.1. Hospitals
    • 4.3.1.1. Hospitals Market, 2021 - 2033 (USD Billion, Units)
  • 4.3.2. Homecare Settings
    • 4.3.2.1. Homecare Settings Market, 2021 - 2033 (USD Billion, Units)
  • 4.3.3. Others
    • 4.3.3.1. Others Market, 2021 - 2033 (USD Billion, Units)

Chapter 5. Injectable Drug Delivery Devices Market: Regional Estimates & Trend Analysis

• 5.1. Injectable Drug Delivery Devices Market: Regional Outlook
• 5.2. North America
  • 5.2.1. North America Injectable Drug Delivery Devices Market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.2.2. U.S.
    • 5.2.2.1. Competitive Scenario
    • 5.2.2.2. Regulatory framework
    • 5.2.2.3. Reimbursement Structure
    • 5.2.2.4. U.S. Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.2.3. Canada
    • 5.2.3.1. Competitive Scenario
    • 5.2.3.2. Regulatory framework
    • 5.2.3.3. Reimbursement Structure
    • 5.2.3.4. Canada Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.2.4. Mexico
    • 5.2.4.1. Competitive Scenario
    • 5.2.4.2. Regulatory framework
    • 5.2.4.3. Reimbursement Structure
    • 5.2.4.4. Mexico Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
• 5.3. Europe
  • 5.3.1. Europe Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.3.2. UK
    • 5.3.2.1. Competitive Scenario
    • 5.3.2.2. Regulatory framework
    • 5.3.2.3. Reimbursement Structure
    • 5.3.2.4. UK Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.3.3. Germany
    • 5.3.3.1. Competitive Scenario
    • 5.3.3.2. Regulatory framework
    • 5.3.3.3. Reimbursement Structure
    • 5.3.3.4. Germany Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.3.4. France
    • 5.3.4.1. Competitive Scenario
    • 5.3.4.2. Regulatory framework
    • 5.3.4.3. Reimbursement Structure
    • 5.3.4.4. France Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.3.5. Italy
    • 5.3.5.1. Competitive Scenario
    • 5.3.5.2. Regulatory framework
    • 5.3.5.3. Reimbursement Structure
    • 5.3.5.4. Italy Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.3.6. Spain
    • 5.3.6.1. Competitive Scenario
    • 5.3.6.2. Regulatory framework
    • 5.3.6.3. Reimbursement Structure
    • 5.3.6.4. Spain Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.3.7. Norway
    • 5.3.7.1. Competitive Scenario
    • 5.3.7.2. Regulatory framework
    • 5.3.7.3. Reimbursement Structure
    • 5.3.7.4. Norway Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.3.8. Sweden
    • 5.3.8.1. Competitive Scenario
    • 5.3.8.2. Regulatory framework
    • 5.3.8.3. Reimbursement Structure
    • 5.3.8.4. Sweden Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.3.9. Denmark
    • 5.3.9.1. Competitive Scenario
    • 5.3.9.2. Regulatory framework
    • 5.3.9.3. Reimbursement Structure
    • 5.3.9.4. Denmark Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
• 5.4. Asia
  • 5.4.1. Asia Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.4.2. China
    • 5.4.2.1. Competitive Scenario
    • 5.4.2.2. Regulatory framework
    • 5.4.2.3. Reimbursement Structure
    • 5.4.2.4. China Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.4.3. Japan
    • 5.4.3.1. Competitive Scenario
    • 5.4.3.2. Regulatory framework
    • 5.4.3.3. Reimbursement Structure
    • 5.4.3.4. Japan Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.4.4. India
    • 5.4.4.1. Competitive Scenario
    • 5.4.4.2. Regulatory framework
    • 5.4.4.3. Reimbursement Structure
    • 5.4.4.4. India Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.4.5. Thailand
    • 5.4.5.1. Competitive Scenario
    • 5.4.5.2. Regulatory framework
    • 5.4.5.3. Reimbursement Structure
    • 5.4.5.4. Thailand Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.4.6. South Korea
    • 5.4.6.1. Competitive Scenario
    • 5.4.6.2. Regulatory framework
    • 5.4.6.3. Reimbursement Structure
    • 5.4.6.4. South Korea Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.4.7. Saudi Arabia
    • 5.4.7.1. Competitive Scenario
    • 5.4.7.2. Regulatory framework
    • 5.4.7.3. Reimbursement Structure
    • 5.4.7.4. Saudi Arabia Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.4.8. UAE
    • 5.4.8.1. Competitive Scenario
    • 5.4.8.2. Regulatory framework
    • 5.4.8.3. Reimbursement Structure
    • 5.4.8.4. UAE Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 5.4.9. Kuwait
    • 5.4.9.1. Competitive Scenario
    • 5.4.9.2. Regulatory framework
    • 5.4.9.3. Reimbursement Structure
    • 5.4.9.4. Kuwait Injectable Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)

Chapter 6. Injectable Drug Delivery Devices Market: Competitive Analysis

• 6.1. Company Categorization
• 6.2. Participant's Overview
• 6.3. Financial Performance
• 6.4. Product Offerings
• 6.5. Company Market Position Analysis
• 6.6. Company Market Share Analysis, 2025 (%)
• 6.7. Strategy Mapping
  • 6.7.1. Product Launches & Approvals
  • 6.7.2. Partnerships & Collaborations
  • 6.7.3. Mergers & Acquisitions
  • 6.7.4. Expansions
  • 6.7.5. Others
• 6.8. Company Profiles
  • 6.8.1. Novo Nordisk A/S
    • 6.8.1.1. Company Overview
    • 6.8.1.2. Financial Performance
    • 6.8.1.3. Product Benchmarking
    • 6.8.1.4. Strategic Initiatives
  • 6.8.2. Sanofi
    • 6.8.2.1. Company Overview
    • 6.8.2.2. Financial Performance
    • 6.8.2.3. Product Benchmarking
    • 6.8.2.4. Strategic Initiatives
  • 6.8.3. Eli Lilly and Company
    • 6.8.3.1. Company Overview
    • 6.8.3.2. Financial Performance
    • 6.8.3.3. Product Benchmarking
    • 6.8.3.4. Strategic Initiatives
  • 6.8.4. AstraZeneca plc
    • 6.8.4.1. Company Overview
    • 6.8.4.2. Financial Performance
    • 6.8.4.3. Product Benchmarking
    • 6.8.4.4. Strategic Initiatives
  • 6.8.5. Pfizer, Inc.
    • 6.8.5.1. Company Overview
    • 6.8.5.2. Financial Performance
    • 6.8.5.3. Product Benchmarking
    • 6.8.5.4. Strategic Initiatives
  • 6.8.6. Merck KGaA
    • 6.8.6.1. Company Overview
    • 6.8.6.2. Financial Performance
    • 6.8.6.3. Product Benchmarking
    • 6.8.6.4. Strategic Initiatives
  • 6.8.7. Teva Pharmaceuticals
    • 6.8.7.1. Company Overview
    • 6.8.7.2. Financial Performance
    • 6.8.7.3. Product Benchmarking
    • 6.8.7.4. Strategic Initiatives
  • 6.8.8. Amgen, Inc.
    • 6.8.8.1. Company Overview
    • 6.8.8.2. Financial Performance
    • 6.8.8.3. Product Benchmarking
    • 6.8.8.4. Strategic Initiatives
  • 6.8.9. Ferring Pharmaceuticals
    • 6.8.9.1. Company Overview
    • 6.8.9.2. Financial Performance
    • 6.8.9.3. Product Benchmarking
    • 6.8.9.4. Strategic Initiatives
  • 6.8.10. AbbVie, Inc.
    • 6.8.10.1. Company Overview
    • 6.8.10.2. Financial Performance
    • 6.8.10.3. Product Benchmarking
    • 6.8.10.4. Strategic Initiatives